Free press releases distribution network?

Agency / Source: MDxHealth, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



MDxHealth's ConfirmMDx™ Test Outperforms PSA in Prostate Cancer Detection Algorithm and Decision for Repeat Biopsy - MDxHealth SA announced two presentations on ConfirmMDx for Prostate Cancer, its test to help urologists rule-out prostate cancer-free men from undergoing unnecessary repeat biopsies, at the upcoming American Urology Association Annual Meeting
MDxHealth's ConfirmMDx™ Test Outperforms PSA in Prostate Cancer Detection Algorithm and Decision for Repeat Biopsy

 

PRZOOM - /newswire/ - Irvine, CA, United States, 2013/04/22 - MDxHealth SA announced two presentations on ConfirmMDx for Prostate Cancer, its test to help urologists rule-out prostate cancer-free men from undergoing unnecessary repeat biopsies, at the upcoming American Urology Association Annual Meeting. NYSE Euronext: MDXH

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• Presentations at 2013 American Urology Association Annual Meeting Discuss;
• How ConfirmMDx for Prostate Cancer and Detection Algorithm Helps Men Avoid Unnecessary;
• Repeat Prostate Biopsies and Aid Urologists to Improve Patient Management.

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced two presentations on ConfirmMDx for Prostate Cancer, its test to help urologists rule-out prostate cancer-free men from undergoing unnecessary repeat biopsies, at the upcoming 2013 American Urology Association (AUA) Annual Meeting in San Diego, CA (May 4-8, 2013). An abstract on the role of ConfirmMDx has been chosen for the "Late-Breaking Science Forum" and key urology experts will present data on the test as part of a panel discussion on novel molecular biomarkers for prostate cancer.

"Late-Breaking Science Forum" Podium Presentation at AUA
In an oral presentation, Prof Wim Van Criekinge will describe how combining the epigenetic ConfirmMDx for Prostate Cancer test with traditional histopathological results and other risk factors, including PSA screening, was shown to improve patient management by helping to stratify men who may avoid unnecessary repeat biopsies from those who may harbor undetected prostate cancer and who merit early repeat biopsy.

Title: "A Model Combining Traditional Risk Factors with Epigenetic Profiling Avoids Unnecessary Repeat Biopsies"
Presented by: Prof Wim Van Criekinge, Head of the Laboratory for Computational Genomics and Bioinformatics (Biobix), University of Ghent, Belgium
Date: Tuesday, May 7th, 2013
Time: 1:00 - 2:30 pm
Location: SDCC 6C, San Diego Convention Center

Clinical Update on Novel Prostate Cancer Biomarkers
Experts in the field of urology, Dr. David Crawford and Dr. Neal Shore will discuss the role new molecular biomarkers, such as MDxHealth's ConfirmMDx and Genomic Health's Oncotype DX, will play in the diagnosis and staging of prostate cancer. The program is supported by the Prostate Conditions Education Council, a consortium of leading physicians, health educators, scientists and prostate cancer advocates, and is intended to outline the clinical utility of these new molecular tests and how they will aid in the improved detection and treatment of prostate cancer.

Title: "Understanding How New Biomarkers Will Assist in the Diagnosis and Prognosis of Prostate Cancer"
Presented by: E. David Crawford, M.D., Head Section of Urologic Oncology, Professor of Urology, Surgery and Radiation Oncology, University of Colorado School of Medicine, Denver, Colorado Neal D. Shore, M.D., FACS, Director, CPI, Carolina Urologic Research Center, Grand Strand Urology/Atlantic Urology Clinics, Myrtle Beach, South Carolina
Date: Tuesday, May 7th, 2013
Time: 10 am
Location: Industry Theatre, Exhibit Hall, San Diego Convention Center

About ConfirmMDx for Prostate Cancer
Over 650,000 American men receive a negative prostate biopsy result each year; though approximately 25% of these men may still harbor occult prostate cancer. This well-documented risk of undetected cancer, often with clinically significant Gleason scores, leads to a high rate of repeat biopsies with over 40% of men receiving at least one repeat biopsy, and many receiving a 3rd and 4th biopsy. Today's gold standard diagnostic approach is the prostate biopsy procedure, collecting 10-12 needle core biopsy samples, however this sampling represents less than 1% of a man's prostate. ConfirmMDx for Prostate Cancer is an epigenetic assay to help urologists distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test is able to detect an epigenetic field effect or "halo" associated with the cancerization process at the DNA level. This molecular "halo" around a cancer lesion can be present despite having a normal appearance under the microscope. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment.

About MDxHealth
MDxHealth (mdxhealth.com) is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, ConfirmMDxTM for Prostate Cancer, has been shown to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain and lung cancers. The company is based in Irvine, California with a European headquarters in Liege, Belgium.

For more information:
Mike Sinclair, Halsin Partners
UK: +44 20 7318 2955 / C: +44 7968 022075 - E: sinclair[.]halsin.com.

Seth Lewis, The Trout Group
US: +1 646 378 2952 - E: slewis[.]troutgroup.com

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: MDxHealth, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


MDxHealth's ConfirmMDx™ Test Outperforms PSA in Prostate Cancer Detection Algorithm and Decision for Repeat Biopsy

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
MDxHealth, Inc. |
Contact: Dr. Jan Groen - MDxHealth.com 
949-812-6979 / +32 4 364 20 70 info[.]mdxhealth.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MDxHealth, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From MDxHealth, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today